ArticleThe Journal of international medical research2020
Comparison of plasma exchange, double plasma molecular adsorption system, and their combination in treating acute-on-chronic liver failure.
Article in The Journal of international medical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05392673 (Comparative Analysis on Short-term Efficacies of Two Kinds of Artificai Liver Method in Treating Severe Hepatitis B.), which is not on this map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparative Analysis on Short-term Efficacies of Two Kinds of Artificai Liver Method in Treating Severe Hepatitis B.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- [Meta-analysis of the therapeutic value of plasma exchange simple or combined with dual plasma molecular adsorption system for liver failure].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022Pooled it
- The Clinical Efficacy of Double Plasma Molecular Absorption System Combined with Plasma Exchange in the Treatment of Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis.Journal of healthcare engineering · 2022Pooled it
- Trial
- Extended Double Plasma Molecular Adsorption Sessions and Bilirubin Clearance: A Case Report.Hemodialysis international. International Symposium on Home Hemodialysis · 2026Article
- Cast nephropathy in the ICU: Early recognition and extracorporeal strategies to improve outcomes.Journal of intensive medicine · 2026Review
- Comparison of Two Artificial Liver Treatments for Acute Liver Failure: A Retrospective Observational Study.Nursing in critical care · 2026Observational
- Technicalities, current evidence, and clinical indications of hemoadsorption in critically ill children.Pediatric nephrology (Berlin, Germany) · 2026Review
- Plasma exchange-based artificial liver support system demonstrates short-term therapeutic efficacy in treating chronic severe hepatitis B.American journal of translational research · 2026Article
- Lamotrigine-associated severe cholestatic drug-induced liver injury requiring artificial liver support and percutaneous biliary drainage: a Case Report.Frontiers in pharmacology · 2026Article
- Efficacy and safety analysis of double plasma molecular adsorption system plus plasma exchange for treating acute-on-chronic liver failure.American journal of translational research · 2026Article
- Subacute liver failure caused by immunotherapy in a patient with gastric cancer was improved after multimodal treatment with artificial liver combined with liver-protective drugs: a case report.Frontiers in immunology · 2026Article
- Acetaminophen Poisoning: Case Reports of Early Liver Dialysis for Hepatic Injury.Clinical case reports · 2025Article
- Association between volume of processed plasma and total bilirubin reduction during plasma adsorption for severe liver disease.European journal of medical research · 2025Observational
- Preliminary experience of combined dual plasma molecular adsorption system and plasma exchange in pediatric acute liver failure: a retrospective case series.BMC pediatrics · 2025Article
- Article
- Comparative Cost-Effectiveness of Two Artificial Liver Therapies in Early-Stage Hepatitis B Virus-Related Acute-on-Chronic Liver Failure: A Retrospective Cohort Study.Therapeutics and clinical risk management · 2025Article
- Machine learning-based algorithms for the prediction of 90-day survival in patients with liver failure receiving artificial liver therapy.Frontiers in physiology · 2025Article
- [Clinical application and technical operation specification of dual plasma molecular adsorption system].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024Article
- A clinical study of non-bioartificial liver DPMAES support system in hepatitis B-related acute-on-chronic liver failure.Scientific reports · 2024Article
- Development and validation of a machine learning model to predict prognosis in liver failure patients treated with non-bioartificial liver support system.Frontiers in medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveOur objective was to compare the effectiveness of nonbiological artificial liver (NBAL) support, particularly short-term (28-day) survival rates, in patients who underwent treatment using double plasma molecular adsorption system (DPMAS), plasma exchange (PE), or combined PE+DPMAS, in addition to comprehensive physical treatment for different stages of acute-on-chronic liver failure (ACLF).
methodsWe retrospectively reviewed clinical data of 135 patients with ACLF who received NBAL treatment between November 2015 and February 2019. The patients were categorized into PE, DPMAS, and PE+DPMAS groups. Short-term effectiveness of treatment was assessed and compared based on selected clinical findings, laboratory parameters, and liver function markers.
resultsCoagulation function improved significantly in all groups after treatment. In the PE and PE+DPMAS groups, prothrombin time decreased to different degrees, whereas plasma thromboplastin antecedent increased significantly after treatment. White blood cell counts increased and platelet counts decreased in all groups after treatment. The model for end-stage liver disease score, Child-Pugh grade, systematic inflammatory syndrome score, and sepsis-related organ failure score decreased in all three groups after treatment.
conclusionsPE, DPMAS, and PE+DPMAS improved disease indicators in all patients with ACLF. The combined treatment improved the short-term effectiveness of treatment, especially in patients with mild ACLF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.